SHL Telemedicine Ltd.

SHL Telemedicine Ltd., an Israeli company, develops and globally markets a range of personal telemedicine solutions across Israel, Europe, and other international territories. The firm specializes in cardiac monitoring devices, offering products such as SmartHeart, a mobile 12-lead ECG instrumental in detecting heart attacks, alongside the CardioSen'C cellular-digital 12-lead ECG transmitter, the portable Cardio'B for 12-lead ECGs, and the handheld Cardio Beeper 12/12, which transmits comprehensive ECG readings to monitoring centers. In addition to cardiology, SHL provides various remote health monitoring tools. These include a central communication module designed to transmit medical data from diverse monitoring devices to its telemedicine centers, the TeleWeight trans-telephonic device for weight tracking, TelePress for remote blood pressure measurements, TeleBreather, an electronic handheld device for assessing lung function, and the TelePulse Oximeter, an electronic handheld diagnostic tool for measuring blood oxygen saturation levels and pulse rate. The company delivers its telemedicine services and devices to subscribers utilizing both telephonic and internet communication platforms. Its clientele spans individual patients, health insurance providers, hospitals, clinics, physicians, and other healthcare organizations. SHL Telemedicine engages in significant collaborations, including an agreement with the Mayo Clinic to evaluate how its FDA-approved SmartHeart 12-lead ECG impacts emergency department visits, re-hospitalizations, and major adverse cardiovascular events among heart attack patients over 90 days post-initial hospitalization. Furthermore, it partners with the Hebrew University of Jerusalem and the Hadassah Medical Center to develop an artificial intelligence solution aimed at predicting future life-threatening cardiac events based on 12-lead ECG monitoring. Founded in 1987, SHL Telemedicine Ltd. is headquartered in Tel Aviv, Israel.